Overrepresentation of IL-17A and IL-22 Producing CD8 T Cells in Lesional Skin Suggests Their Involvement in the pathogenesis of psoriasis

PLoS ONE

Volumn 5, Issue 11, 2010, Pages

  Res, Pieter C M ^a   Piskin, Gamze ^a   de Boer, Onno J ^a   van der Loos, Chris M ^a   Teeling, Peter ^a   Bos, Jan D ^a   Teunissen, Marcel B M ^a  

^a UNIVERSITY OF AMSTERDAM   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

INTERLEUKIN 17; INTERLEUKIN 22; INTERLEUKIN DERIVATIVE; INTERLEUKIN-22;

ADULT; ARTICLE; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELL ISOLATION; CLINICAL ARTICLE; CONTROLLED STUDY; CYTOKINE PRODUCTION; DENDRITIC CELL; HELPER CELL; HUMAN; HUMAN CELL; HUMAN TISSUE; IN VITRO STUDY; LYMPHOCYTE ACTIVATION; MACROPHAGE; MALE; MAST CELL; NEUTROPHIL; PATHOGENESIS; PROTEIN EXPRESSION; PSORIASIS; TH17 CELL; TH22 CELL; FLOW CYTOMETRY; IMMUNOHISTOCHEMISTRY; METABOLISM; MIDDLE AGED; PATHOLOGY; SKIN;

ADULT; CD4-POSITIVE T-LYMPHOCYTES; CD8-POSITIVE T-LYMPHOCYTES; DENDRITIC CELLS; FLOW CYTOMETRY; HUMANS; IMMUNOHISTOCHEMISTRY; INTERLEUKIN-17; INTERLEUKINS; MACROPHAGES; MALE; MAST CELLS; MIDDLE AGED; NEUTROPHILS; PSORIASIS; SKIN;

EID: 78649666553     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0014108     Document Type: Article

References (53)

1. Teunissen MB, Piskin G, Res PC, de Groot M, Picavet DI, et al. (2007) State of the art in the immunopathogenesis of psoriasis. G Ital Dermatol Venereol 142: 229-242.
2. Bos JD, de Rie MA, Teunissen MB, Piskin G (2005) Psoriasis: dysregulation of innate immunity. Br J Dermatol 152: 1098-1107.
3. Bos JD (2007) Psoriasis, innate immunity, and gene pools. J Am Acad Dermatol 56: 468-471.
4. Nickoloff BJ, Xin H, Nestle FO, Qin JZ (2007) The cytokine and chemokine network in psoriasis. Clin Dermatol 25: 568-573.
5. Austin LM, Ozawa M, Kikuchi T, Walters IB, Krueger JG (1999) The majority of epidermal T cells in Psoriasis vulgaris lesions can produce type 1 cytokines, interferon-gamma, interleukin-2, and tumor necrosis factor-alpha, defining TC1 (cytotoxic T lymphocyte) and TH1 effector populations: a type 1 differentiation bias is also measured in circulating blood T cells in psoriatic patients. J Invest Dermatol 113: 752-759.
6. Szabo SK, Hammerberg C, Yoshida Y, Bata-Csorgo Z, Cooper KD (1998) Identification and quantitation of interferon-gamma producing T cells in psoriatic lesions: Localization to both CD4(+) and CD8(+) subsets. J Invest Dermatol 111: 1072-1078.
7. Zhou XH, Krueger JG, Kao MCJ, Lee E, Du FH, et al. (2003) Novel mechanisms of T-cell and dendritic cell activation revealed by profiling of psoriasis on the 63,100-element oligonucleotide array. Physiol Genomics 13: 69-78.
8. Cua DJ, Sherlock J, Chen Y, Murphy CA, Joyce B, et al. (2003) Interleukin-23 rather than interleukin-12 is the critical cytokine for autoimmune inflammation of the brain. Nature 421: 744-748.
9. Langrish CL, Chen Y, Blumenschein WM, Mattson J, Basham B, et al. (2005) IL-23 drives a pathogenic T cell population that induces autoimmune inflammation. J Exp Med 201: 233-240.
10. Murphy CA, Langrish CL, Chen Y, Blumenschein C, McClanahan T, et al. (2003) Divergent pro- and Antiinflammatory roles for IL-23 and IL-12 in joint autoimmune inflammation. J Exp Med 198: 1951-1957.
11. Stritesky GL, Yeh N, Kaplan MH (2008) IL-23 Promotes Maintenance but Not Commitment to the Th17 Lineage. J Immunol 181: 5948-5955.
12. Wiekowski MT, Leach MW, Evans EW, Sullivan L, Chen SC, et al. (2001) Ubiquitous transgenic expression of the IL-23 subunit p19 induces multiorgan inflammation, runting, infertility, and premature death. J Immunol 166: 7563-7570.
13. Chan JR, Blumenschein W, Murphy E, Diveu C, Wiekowski M, et al. (2006) IL-23 stimulates epidermal hyperplasia via TNF and IL-20R2-dependent mechanisms with implications for psoriasis pathogenesis. J Exp Med 203: 2577-2587.
14. Zheng Y, Danilenko DM, Valdez P, Kasman I, Eastham-Anderson J, et al. (2007) Interleukin-22, a T(H)17 cytokine, mediates IL-23-induced dermal inflammation and acanthosis. Nature 445: 648-651.
15. Lee E, Trepicchio WL, Oestreicher JL, Pittman D, Wang F, et al. (2004) Increased expression of interleukin 23 p19 and p40 in lesional skin of patients with psoriasis vulgaris. J Exp Med 199: 125-130.
16. Piskin G, Sylva-Steenland RM, Bos JD, Teunissen MB (2006) In vitro and in situ expression of IL-23 by keratinocytes in healthy skin and psoriasis lesions: Enhanced expression in psoriatic skin. J Immunol 176: 1908-1915.
17. Capon F, di Meglio P, Szaub J, Prescott NJ, Dunster C, et al. (2007) Sequence variants in the genes for the interleukin-23 receptor (IL23R) and its ligand (IL12B) confer protection against psoriasis. Hum Genet 122: 201-206.
18. Cargill M, Schrodi SJ, Chang M, Garcia VE, Brandon R, et al. (2007) A largescale genetic association study confirms IL12B and leads to the identification of IL23R as psoriasis-risk genes. Am J Hum Genet 80: 273-290.
19. Gottlieb AB, Cooper KD, McCormick TS, Toichi E, Everitt DE, et al. (2007) A phase 1, double-blind, placebo-controlled study evaluating single subcutaneous administrations of a human interieukin-12/23 monoclonal antibody in subjects with plaque psoriasis. Cur Med Res Opin 23: 1081-1092.
20. Kauffman CL, Aria N, Toichi E, McCormick TS, Cooper KD, et al. (2004) A phase I study evaluating the safety, pharmacokinetics, and clinical response of a human IL-12 p40 antibody in subjects with plaque psoriasis. J Invest Dermatol 123: 1037-1044.
21. Krueger GG, Langley RG, Leonardi C, Yeilding N, Guzzo C, et al. (2007) A human interleukin-12/23 monoclonal antibody for the treatment of psoriasis. N Engl J Med 356: 580-592.
22. Toichi E, Torres G, McCormick TS, Chang T, Mascelli MA, et al. (2006) An anti-IL-12p40 antibody down-regulates type 1 cytokines, chemokines, and IL- 12/IL-23 in psoriasis. J Immunol 177: 4917-4926.
23. Teunissen MB, Koomen CW, Malefyt RD, Wierenga EA, Bos JD (1998) Interleukin-17 and interferon-gamma synergize in the enhancement of proinflammatory cytokine production by human keratinocytes. J Invest Dermatol 111: 645-649.
24. Wilson NJ, Boniface K, Chan JR, McKenzie BS, Blumenschein WM, et al. (2007) Development, cytokine profile and function of human interleukin 17- producing helper T cells. Nature Immunol 8: 950-957.
25. Nograles KE, Zaba LC, Guttman-Yassky E, Fuentes-Duculan J, Suarez-Farinas M, et al. (2008) Th17 cytokines interleukin (IL)-17 and IL-22 modulate distinct inflammatory and keratinocyte-response pathways. Br J Dermatol 159: 1092-1102.
26. Zaba LC, Cardinale I, Gilleaudeau P, Sullivan-Whalen M, Suarez-Farinas M, et al. (2007) Amelioration of epidermal hyperplasia by TNF inhibition is associated with reduced Th17 responses. J Exp Med 204: 3183-94.
27. Kolls JK, Linden A (2004) Interleukin-17 family members and inflammation. Immunity 21: 467-476.
28. Ma HL, Liang S, Li J, Napierata L, Brown T, et al. (2008) IL-22 is required for Th17 cell-mediated pathology in a mouse model of psoriasis-like skin inflammation. J of Clin Invest 118: 597-607.
29. Boniface K, Guignouard E, Pedretti N, Garcia M, Delwail A, et al. (2007) A role for T cell-derived interleukin 22 in psoriatic skin inflammation. Clin Exp Immunol 150: 407-415.
30. Sa M, Valdez PA, Wu JF, Jung K, Zhong F, et al. (2007) The effects of IL-20 subfamily cytokines on reconstituted human epidermis suggest potential roles in cutaneous innate defense and pathogenic adaptive immunity in psoriasis. J Immunol 178: 2229-2240.
31. Wolk K, Witt E, Wallace E, Docke WD, Kunz S, et al. (2006) IL-22 regulates the expression of genes responsible for antimicrobial defense, cellular differentiation, and mobility in keratinocytes: a potential role in psoriasis. Eur J Immunol 36: 1309-1323.
32. Nograles KE, Zaba LC, Shemer A, Fuentes-Duculan J, Cardinale I, et al. (2009) IL-22-producing "T22'' T cells account for upregulated IL-22 in atopic dermatitis despite reduced IL-17-producing T(H)17 T cells. J Allergy Clin Immunol 123: 1244-1252.
33. Bos JD, Hulsebosch HJ, Krieg SR, Bakker PM, Cormane RH (1983) Immunocompetent Cells in Psoriasis - Insitu Immunophenotyping by Monoclonal- Antibodies. Arch Dermatol Res 275: 181-189.
34. Vissers WH, Arndtz CH, Muys L, Van Erp PE, De Jong EM, et al. (2004) Memory effector (CD45RO+) and cytotoxic (CD8+) T cells appear early in the margin zone of spreading psoriatic lesions in contrast to cells expressing natural killer receptors, which appear late. Br J Dermatol 150: 852-859.
35. Fan X, Yang S, Huang W, Wang ZM, Sun LD, et al. (2008) Fine mapping of the psoriasis susceptibility locus PSORS1 supports HLA-C as the susceptibility gene in the Han Chinese population. Plos Genet 4.
36. Nair RP, Stuart PE, Nistor I, Hiremagalore R, Chia NVC, et al. (2006) Sequence and haplotype analysis supports HLA-C as the psoriasis susceptibility gene. Am J Hum Genet 78: 827-851.
37. van der Loos CM (2008) Multiple immunoenzyme staining: Methods and visualizations for the observation with spectral imaging. J Histochem & Cytochem 56: 313-328.
38. Streeck H, Cohen KW, Jolin JS, Brockman MA, Meier A, et al. (2008) Rapid ex vivo isolation and long-term culture of human Th17 cells. J Immunol Methods 333: 115-125.
39. Duhen T, Geiger R, Jarrossay D, Lanzavecchia A, Sallusto F (2009) Production of interleukin 22 but not interleukin 17 by a subset of human skin-homing memory T cells. Nature Immunol 10: 857-U72.
40. Trifari S, Kaplan CD, Tran EH, Crellin NK, Spits H (2009) Identification of a human helper T cell population that has abundant production of interleukin 22 and is distinct from T-H-17, T(H)1 and T(H)2 cells. Nature Immunol 10: 864- U73.
41. Bos JD, Hagenaars C, Das PK, Krieg SR, Voorn WJ, et al. (1989) Predominance of Memory T-Cells (CD4+, CDw29+) Over Naive T-Cells (CD4+, CD45R+) in Both Normal and Diseased Human-Skin. Arch Dermatol Res 281: 24-30.
42. Johnston A, Gudjonsson JE, Sigmundsdottir H, Love TJ, Valdimarsson H (2004) Peripheral blood T cell responses to keratin peptides that share sequences with streptococcal M proteins are largely restricted to skin-homing CD8(+) T cells. Clin Exp Immunol 138: 83-93.
43. Lowes MA, Kikuchi T, Fuentes-Duculan J, Cardinale I, Zaba LC, et al. (2008) Psoriasis vulgaris lesions contain discrete populations of Th1 and Th17 T cells. J. Invest Dermatol 128: 1207-1211.
44. Kryczek I, Bruce AT, Gudjonsson JE, Johnston A, Aphale A, et al. (2008) Induction of IL-17(+) T cell trafficking and development by IFN-gamma: Mechanism and pathological relevance in psoriasis. J Immunol 181: 4733-4741.
45. Hueber AJ (2010) Cutting Edge: Mast Cells Express IL-17A in Rheumatoid Arthritis Synovium. J Immunol 184: 3336-3340.
46. de Boer OJ, van der Meer JJ, Teeling P, van der Loos CM, Idu MM, et al. (2010) Differential expression of interleukin-17 family cytokines in intact and complicated human atherosclerotic plaques. J Pathol 220: 499-508.
47. Ikeda K, Nakajima H, Suzuki K, Kagami SI, Hirose K, et al. (2003) Mast cells produce interleukin-25 upon Fc epsilon RI-mediated activation. Blood 101: 3594-3596.
48. Weaver CT, Hatton RD, Mangan PR, Harrington LE (2007) IL-17 family cytokines and the expanding diversity of effector T cell lineages. Annu Rev Immunol 25: 821-852.
49. Liang SC, Tan XY, Luxenberg DP, Karim R, Dunussi-Joannopoulos K, Collins M, et al. (2006) Interleukin (IL)-22 and IL-17 are coexpressed by Th17 cells and cooperatively enhance expression of antimicrobial peptides. J Exp Med 203: 2271-2279.
50. Yang XX, Chang SH, Park H, Nurieva R, Shah B, Acero L, et al. (2008) Regulation of inflammatory responses by IL-17F. J Exp Med 205: 1063-1075.
51. Zaba LC, Fuentes-Duculan J, Eungdamrong NJ, Abello MV, Novitskaya I, et al. (2009) Psoriasis Is Characterized by Accumulation of Immunostimulatory and Th1/Th17 Cell-Polarizing Myeloid Dendritic Cells. J Invest Dermatol 129: 79-88.
52. Fuschiotti P, Medsger TA, Morel PA (2009) Effector CD8+ T Cells in Systemic Sclerosis Patients Produce Abnormally High Levels of Interleukin-13 Associated With Increased Skin Fibrosis. Arthritis Rheum 60: 1119-1128.
53. Friese MA, Fugger L (2009) Pathogenic CD8(+) T Cells in Multiple Sclerosis. Ann Neurol 66: 132-141.